Chromogranin A and chromogranin B in pancreatic neuroendocrine tumors
https://doi.org/10.33667/2078-5631-2020-8-26-28
Abstract
For the first time in Russia a comparative study of chromogranin A (CgA) and chromogranin B (CgB) in neuroendocrine tumors (NETs) of the pancreas was performed. We examined 50 primary patients with pancreatic NETs and 42 healthy people. The determination of CgA and CgB was performed in blood serum using standard enzyme-linked immunoassay test-systems (Chromogranin A NEOLISA, Eurodiagnostica; Human Chromogranin B, USCN). The levels of CgA and CgB in pancreatic NETs significantly differed from the control group. There was found the association between CgA levels and the dissemination of the process, while CgB demonstrated the properties of a marker independent from the tumor dissemination. The diagnostic sensitivity of CgA was 76 %, CgB – 68 %. Complex determination of CgA and CgB enhanced the diagnostic sensitivity to 84 %. Our data indicate the potential usefulness of complex CgA and CgB in the diagnosis of pancreatic NETs.
About the Authors
N. V. Lyubimova
National Medical Research Centre of Oncology n. a. N. N. Blokhin
Russian Federation
Russian Federation
Moscow
Yu. S. Timofeev
National Medical Research Centre of Oncology n. a. N. N. Blokhin
Russian Federation
Russian Federation
Moscow
A. V. Lebedeva
National Medical Research Centre of Oncology n. a. N. N. Blokhin
Russian Federation
Russian Federation
Moscow
N. E. Kushlinsky
National Medical Research Centre of Oncology n. a. N. N. Blokhin
Russian Federation
Russian Federation
Moscow
References
1. Orditura M., Petrillo A., Ventriglia J., Laterza M. M., Fabozzi A. Pancreatic neuroendocrine tumors: nosography, management and treatment // Int. J. Surg. – 2016. – Vol. 28. – N 1. – P. 56–62.
2. Oberg K. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours // Endocr. Relat. Cancer. 2011. – Vol. 18. N 1. – P. 17–25.
3. Modlin I. M., Gustafsson B. I., Moss S. F., Pavel M., Tsolakis A. V., Kidd M. Chromogranin A – biological function and clinical utility in neuroendocrine tumor disease // Ann. Surg. Oncol. – 2010. – Vol. 17. – N 9. – P. 2427–2443.
4. Aluri V., Dilon J. S. Biochemical testing in neuroendocrine tumors // Endocrinol. Metab. Clin. North Am. – 2017. – Vol. 46. – N 3. – P. 669–677.
5. Vinik A. I., Silva M. P., Woltering E. A., Go V. L., Warner R., Caplin M. Biochemical testing for neuroendocrine tumors // Pancreas. – 2009. – Vol. 38. – N 8. – P. 876–889.
6. Любимова Н. В., Чурикова Т. К., Кушлинский Н. Е. Хромогранин А – биохимический маркер нейроэндокринных опухолей // Бюллетень экспериментальной биологии и медицины. – 2015. – Том 160. – № 1. – С. 657–660.
7. Любимова Н. В., Тимофеев Ю. С.. Чурикова Т. К., Кузьминов А. Е., Кушлинский Н. Е. Значение хромогранина А в диагностике и прогнозе нейроэндокринных опухолей // Медицинский Алфавит. – 2019. – Том 2. – № 17. – С. 19–22.
8. Yao J. C., Pavel M., Phan A.T, Kulke M. H., Hoosen S., St Peter J., Cherfi A., Oberg K. E. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus // J. Clin. Endocrinol. Metab. – 2011. – Vol. 96. – N 12. – P. 3741–3749.
9. Han X., Zhang C., Tang M., Xu X., Liu L., Ji Y., Pan B., Lou W. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases // Eur. J. Gastroenterol. Hepatol. – 2015. – Vol. 27. – N 5. – P. 527–535.
10. Massironi S., Rossi R. E., Casazza G., Conte D, Ciafardini C., Galeazzi M., Peracchi M. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution // Neuroendocrinology. – 2014. – Vol. 100. – N 2–3. – P. 240–249.
11. Chen C., Zheng Z., Li B., Zhou L., Pang J., Wu W., Zheng C., Zhap Y. Pancreatic VIPomas from China: Case reports and literature review // Pancreatology. – 2019. – Vol. 19. – N 1. – P. 44–49.
12. Guettier J. M., Gorde P. Insulin secretion and insulin-producing tumors // Expert. Rev. Endocrinol. Metab. – 2010. – Vol. 5. – N 2. – P. 217–227.
13. Cheng Y., Sun Z., Bai C., Yan X., Qin R., Meng C., Ying H. Serum chromogranin A levels for the diagnosis and follow-up of well-differentiated non-functioning neuroendocrine tumors // Tumour Biol. – 2016. – Vol. 37. – N 3. – P. 2863–2869.
14. Stridsberg M., Eriksson B., Fellstrom B., Kristiansson G., Janson E. V. Measurment of chromogranin B can serve as a complement to chromogranin A // Regul. Pept. – 2007. – Vol. 139. – N 1–3. – P. 80–83.
15. Stridsberg M., Oberg K., Li Q., Engstrom U., Lundqvist G. Measurment of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours // J. Endocrinol. – 1995. – Vol. 144. – N 1. – P. 49–59.
16. Miki M., Tetuhide I., Hijoka M., Lee L., Yasunaga K., Ueda K., Fujiyama T., Tachibana Y., Kawabe K., Jensen T. R., Ogawa Y. Utility of chromogranin B as a biomarker in Japanese patients with pancreatic neuroendocrine tumors // Jpn. J. Clin. Oncol. – 2017. – Vol. 47. – N 6. – P. 520–528.
Review
For citations:
Lyubimova N.V., Timofeev Yu.S., Lebedeva A.V., Kushlinsky N.E. Chromogranin A and chromogranin B in pancreatic neuroendocrine tumors. Medical alphabet. 2020;(8):26-28. (In Russ.) https://doi.org/10.33667/2078-5631-2020-8-26-28
Views:
822
Email this article 